Oral DS107 Found to Reverse the Molecular Signature of Moderate to...

DS Biopharma (DS), a privately held biopharmaceutical company, today announced that oral treatment with DS107 reversed the molecular signature of Atopic Dermatitis (AD) patients in a phase 2b clinical...(PRWeb October 18, 2018)Read the full story at https://www.prweb.com/releases/oral_ds107_found_to_reverse_the_molecular_signature_of_moderate_to_severe_atopic_dermatitis_patients_in_a_phase_2_trial/prweb15851261.htm
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news